FDA challenges stem cell therapy companies

FDA wings
The Food and Drug Administration is stepping up its oversight of companies selling unproven and unlicensed stem-cell therapies and emerging industry with a spotty ethical and medical track record.
 
View the original article here: FDA challenges stem cell therapy companies
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend